Date: 15th May 2026

BSE Limited	**National Stock Exchange of India Limited**
Corporate Relationship Department	The Manager, Listing Department
Phiroze Jeejeebhoy Towers,	"Exchange Plaza"
Dalal Street,	Bandra - Kurla Complex, Bandra (E)
Mumbai- 400 001.	Mumbai - 400 051
BSE – Scrip Code: 517556	**NSE Symbol: PVP**
	Debt-18PVL29A, 18PVL29

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors of the company, at its meeting held on Friday, 15th May 2026 at 03:00 PM (IST) through video conferencing, inter alia, considered and approved the following matters:

1. Approval for Change of Name of the Company

The Board approved the change in the name of the company from "PVP Ventures Limited" to **"Evervie Health Limited"** and the consequential alteration to the Name Clause of the Memorandum of Association and Articles of Association of the company, subject to the approval of the shareholders of the company.

2. Appointment of Additional Directors (Non-Executive Independent)

The Board approved the appointment of the following persons as Additional Directors in the category of Non-Executive Independent Directors of the company with effect from 15th May 2026, subject to the approval of shareholders.

a. Ms. Saloni Khandelwal (DIN: 00014590)
b. Dr. Ellen Feehan (DIN: 11716152)
c. Mr. Srivatsan Kalyanasundaram (DIN: 11719208)

The details required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026 (as amended from time to time), are enclosed as **Annexure – I**.

3. Appointment of Additional Director and Chief Operating Officer (COO)

The Board approved the appointment of Dr. Neeraja Nagarajan as an Additional Director of the company and also as Chief Operating Officer (COO) of the company, subject to the approval of shareholders.

The appointment shall be on such terms and conditions, including remuneration and other allied matters, as may be approved by the Board from time to time. The appointment shall take effect from 15th May 2026.

The details required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026 (as amended from time to time), are enclosed as **Annexure – II**.

4. Appointment of Chief Financial Officer (CFO)

The Board approved the appointment of Mr. Raghu Chaitanya as the Chief Financial Officer (CFO) and Key Managerial Personnel of the company with effect from 1st June 2026.

The details required pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026 (as amended from time to time), are enclosed as **Annexure – III**.

5. Formation of International Holding Company

The Board discussed and approved the proposal for formation of an International Holding Company in furtherance of the company's strategic growth and expansion initiatives in the healthcare sector in the Middle East and the United Kingdom.

The Management has been authorized to evaluate and undertake necessary steps in this regard, subject to applicable statutory and regulatory approvals.

The Board meeting Commenced at 03.00 P.M and Concluded at 05:30 PM (IST)

Request you to kindly take the same on record

Thanking You,

Yours Faithfully,

For **PVP VENTURES LIMITED**

PRASAD VEERA POTLURI

Digitally signed by PRASAD VEERA POTLURI
Date: 2026.05.15 17:36:04 +05'30'

Prasad V Potluri
Chairman and Managing Director

PVP Ventures Ltd.
Corp. Office: Plot No. 83 & 84 4th Floor Punnaiah Plaza Road No. 2 Banjara Hills Hyderabad - 500 034 T: +91 40 6730 9999 F: +91 40 6730 9988
Regd. Office: KRM Centre 9th Floor No. 2 Harrington Road Chetpet Chennai - 600 031 T: +91 44 3028 5570 F: +91 44 3028 5571
info@pvpglobal.com | pvpglobal.com

PVP VENTURES LIMITED
CIN : L72300TN1991PLC020122

Annexure - I

Details required as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, and SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026

S.No	Details	Mr. Srivatsan Kalyanasundaram	Ms. Ellen Feehan	Ms. Saloni Khandelwal
1.	Reason for Change viz, appointment, ~~resignation, removal, death or otherwise~~	Appointment as an Additional Director in the category of Non-Executive Independent Director	Appointment as an Additional Director in the category of Non-Executive Independent Director	Appointment as an Additional Director in the category of Non-Executive Independent Director
2.	Date of appointment/~~rea ppointment / Cessation (as applicable) &~~ term of Appointment/~~re appointment~~	With effect from 15th May, 2026, subject to approval of shareholders.	With effect from 15th May, 2026, subject to approval of shareholders.	With effect from 15th May, 2026, subject to approval of shareholders.
3.	Brief Profile	Mr. Srivatsan Kalyanasundaram is a seasoned business leader with nearly three decades of experience across multinational enterprises, start-ups, and regulated industries. He has held senior leadership roles with organizations including Vodafone Group and McKinsey & Company, with extensive international experience across the United Kingdom, Europe, and the Middle East. He is currently serving as Chief Executive	Ms. Ellen Feehan is a qualified medical doctor and management professional. She graduated from Trinity College Dublin with qualifications of MB, BCh, BAO and holds an MBA from University College Dublin. She has also obtained professional qualifications in Surgery and Plastic Surgery from the Royal College of Surgeons in Ireland, including FRCSI and FRCS (Plast).	Ms. Saloni Khandelwal is a seasoned transaction advisory professional with nearly two decades of consulting experience across leading advisory firms. She is the Founder of Transaction Square, a transaction advisory and family office firm. She was associated with PwC for over seven years and served as a Partner in the Mergers & Acquisitions Tax practice in her last role. Prior to this, she was associated with

PVP VENTURES LIMITED
CIN : L72300TN1991PLC020122

		Officer Advisor and Interim Chief Operating Officer at a Public Investment Fund-backed fintech platform in Saudi Arabia. His expertise spans strategy, technology, governance, cybersecurity, digital transformation, and business scale-up in regulated environments. He holds an MBA from HEC Paris / Ross School of Business, an M.Sc. in Economics, and a Bachelor of Engineering from BITS Pilani.		KPMG for over a decade. Her areas of expertise include transaction advisory, business restructuring, mergers and acquisitions, investment strategies both inbound and outbound, private equity, fundraising, tax and regulatory matters. She also specializes in succession planning for family wealth, family constitutions and charters, and establishment of trust structures in India and overseas. She has advised a diverse portfolio of domestic and international clients across sectors including real estate, renewable energy, infrastructure, pharmaceuticals, healthcare, media, and IT/ITeS.
4.	Disclosure of relationships between Directors (in case of appointment of a director)	None	None	None

Annexure-II

Details required as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, and SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026

S.NO.	Details	Dr. Neeraja Nagarajan
1	Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~	Appointment as Additional Director and as Chief Operating Officer (COO)
2	Date of appointment/~~cessation~~ (as applicable) and term of appointment	With effect from May 15, 2026 subject to approval of shareholders.
3	Brief Profile (in case of appointment)	Dr. Neeraja Nagarajan is a medical doctor, public health scientist, and strategic healthcare consultant with extensive experience in healthcare systems, operational strategy, and business transformation. She has previously been associated with McKinsey & Company, where she advised on healthcare initiatives, strategic planning, and operational transformation programs. Her expertise spans healthcare management, public health advisory, operational excellence, and execution of large-scale strategic and business transformation initiatives.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

PVP VENTURES LIMITED
CIN : L72300TN1991PLC020122

Annexure-III

Details required as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, and SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dt.30th January 2026

S.NO.	Details	Mr. Raghu Chaitanya
1	Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~	Appointment as Chief Financial Officer of the Company
2	Date of appointment/~~cessation~~ (as applicable) and term of appointment	With effect from June 1, 2026
3	Brief Profile (in case of appointment)	Mr. Raghu Chaitanya is a qualified Chartered Accountant with over 15 years of extensive experience in finance, accounting, taxation, financial reporting, strategic planning, and financial management. He has held senior leadership positions with reputed organizations including Finolex Industries Limited, Orient Cement Limited, and ACC Limited. His areas of expertise include financial planning & analysis, Ind AS compliance, MIS reporting, working capital management, internal controls, ERP and SAP implementation, process automation, and finance transformation initiatives.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

PVP VENTURES LIMITED
CIN : L72300TN1991PLC020122